Department of Physics, University of Kerala, Thiruvananthapuram, Kerala 695015, India.
College of Biotechnology, Al-Qasim Green University, Babylon 51013, Iraq.
ACS Biomater Sci Eng. 2024 Oct 14;10(10):6299-6313. doi: 10.1021/acsbiomaterials.4c01039. Epub 2024 Sep 2.
Magnetic nanoparticles used for targeted drug administration present a promising approach in cancer treatment owing to its notable advantages, such as targeted and enhanced encapsulation ability and improved bio protection compared with conventional drug delivery methods. Au shell-iron core nanoparticles (FeO@Au) were manufactured by a chemical process, coated with dextran to encapsulate curcumin, and functionalized for precision drug delivery using folic acid to combat liver cancer. Dynamic light scattering, scanning electron microscopy, transmission electron microscopy, vibrational spectroscopy, and magnetometry were applied to assess the synthesis of the FeO@Au-DEX-CU-FA compound. The mean size, zeta potential, and polydispersity of FeO@Au-DEX-CU-FA were 63.3 ± 2.33 nm, -68.3 ± 1.78 mV, and 0.041 ± 0.008, respectively. Molecular docking models were created to examine the relationship between FeO@Au-CU and BCL-XL, BAK, and to identify potential binding sites. The loading efficiency and release profile tests examined the medication delivery system's ability. MTT assay was subsequently utilized to determine the optimal dosage and therapeutic efficacy of FeO@Au-DEX-CU-FA on cancer SNU-449 and healthy THLE-2 cell lines. Flow cytometry demonstrated that FeO@Au-DEX-CU-FA effectively induced cancer cell death. FeO@Au-DEX-FA showed a regulated release profile of free curcumin at 37 °C and pH values of 7.4 and 5.4. Real-time PCR revealed increased BAK expression and decreased BCL-XL expression. Nude tumor-bearing mice were used for in vivo experiments. FeO@Au-DEX-CU-FA treatment dramatically reduced the swelling size compared with free CU and control treatments. It also resulted in a longer lifespan, expanded splenocyte proliferation, increased IFN-γ levels, and decreased IL-4 levels. The regular cells showed no cytotoxic effect compared with the cancer type, confirming that FeO@Au-DEX-CU-FA maintained its potent anticancer actions. The data suggests that FeO@Au-DEX-CU-FA possesses a promising potential as a therapeutic agent for combating tumors.
磁性纳米粒子因其靶向和增强包封能力以及与传统药物输送方法相比提高生物保护等显著优势，在癌症治疗中具有广阔的应用前景。通过化学过程制造 Au 壳-铁核纳米粒子（FeO@Au），用葡聚糖包裹姜黄素，并用叶酸进行功能化，以实现精准药物输送，用于治疗肝癌。应用动态光散射、扫描电子显微镜、透射电子显微镜、振动光谱和磁强计评估 FeO@Au-DEX-CU-FA 化合物的合成。FeO@Au-DEX-CU-FA 的平均粒径、Zeta 电位和多分散性分别为 63.3±2.33nm、-68.3±1.78mV 和 0.041±0.008。建立分子对接模型以研究 FeO@Au-CU 与 BCL-XL、BAK 之间的关系，并确定潜在的结合位点。负载效率和释放曲线测试检查了药物输送系统的能力。随后使用 MTT 测定法确定 FeO@Au-DEX-CU-FA 在癌症 SNU-449 和健康 THLE-2 细胞系中的最佳剂量和治疗效果。流式细胞术表明 FeO@Au-DEX-CU-FA 能有效诱导癌细胞死亡。FeO@Au-DEX-FA 在 37°C 和 pH 值为 7.4 和 5.4 时表现出游离姜黄素的调控释放曲线。实时 PCR 显示 BAK 表达增加，BCL-XL 表达减少。使用裸鼠进行体内实验。与游离 CU 和对照处理相比，FeO@Au-DEX-CU-FA 处理显著减小肿瘤肿胀大小。它还导致更长的寿命、扩展的脾细胞增殖、增加 IFN-γ 水平和降低 IL-4 水平。与癌症类型相比，正常细胞没有显示出细胞毒性作用，这证实了 FeO@Au-DEX-CU-FA 保持其有效的抗癌作用。数据表明，FeO@Au-DEX-CU-FA 具有作为抗肿瘤治疗剂的潜在应用前景。
